1. Introduction {#sec1}
===============

Limb girdle muscular dystrophy type 2D (LGMD-2D) is an autosomal recessive muscular disease caused by genetic defects in sarcolemmal alpha sarcoglycan (*α*-SGC) glycoprotein. Alpha-SGC or adhalin, one of the four sarcoglycans (SGCs), is essential for membrane integrity during muscle contraction and provides a scaffold for important signaling molecules \[[@B1]--[@B3]\]. Alpha-SGC is encoded by the sarcoglycan alpha gene (SGCA) located on chromosome 17q21 \[[@B1], [@B4]\]. LGMD-2D predominantly affects proximal muscles around the scapular and the pelvic girdles. LGMD-2D has a very heterogeneous phenotype. The age of onset, rate of progression, and the severity of disease can vary between and also within affected families. The most clinically severe course is generally observed when the sarcolemmal *α*-SGC is totally absent whereas milder phenotypes are observed when residual proteins are present \[[@B1]--[@B4]\]. Interestingly, a mutation in any SGC gene can lead to a reduction or absence of the other SGCs \[[@B4]--[@B7]\]. It was previously reported that the SGCA gene must be evaluated first if there is a concomitant absence of *α*-SGC and gamma- (*γ*-) SGC \[[@B4]\].

The differential diagnosis for LGMD-2D includes Duchenne and Becker muscular dystrophies (DMD/BMD) and it is impossible to reach a diagnosis on clinical grounds alone. Therefore, immunohistochemical staining of a muscle biopsy and molecular genetic analysis are mandatory for the correct diagnosis \[[@B3], [@B5], [@B8], [@B9]\]. In this report, the patient\'s genotype was a previously unknown 7 bp deletion in exon 3. This finding adds to the growing spectrum of mutations in the alpha-sarcoglycan gene. Finally, we also discuss important considerations in the differential diagnosis of the muscular dystrophies.

2. Case Report {#sec2}
==============

A 5-year-old boy had second degree consanguineous parents from Turkey without an ancestral history of neuromuscular disorders. There were no complications during pregnancy, and antenatal signs of muscular disorders such as polyhydramnios and reduced fetal movements were not noted. Cognitive and motor development was normal. At the time of presentation, his previously undetected mild muscle weakness was predominantly proximal. Deep tendon reflexes were present and he had no contractures. He was walking normally but he had mild difficulty when climbing stairs and running. Pulmonary function tests were normal. His creatinine phosphokinase (CPK) levels were between 9000 and 15000 units per liter (normal \< 250 U/L), and there were myopathic changes on electromyography. Because of the very high CPK level, muscular dystrophy was suspected and, after informed consent, samples were obtained for histopathology, immunohistochemistry, and molecular genetics testing.

A muscle biopsy specimen from the left gastrocnemius muscle of the patient was frozen in isopentane that was precooled to −160°C in liquid nitrogen. Cryosections were immunostained for dystrophin using a polyclonal antibody (Neomarkers), with a monoclonal spectrin antibody (Novocastra) as a control. A neonatal myosin heavy chain (Neonatal myosin, Novocastra) antibody was used for the identification of pathological immature myofibers. SGCs were detected with anti-*α*-, -*β*-, -*δ*-, and -*γ*-SGC antibodies (Novocastra).

Peripheral blood specimens were collected from the proband and parents. Genomic DNA was extracted from whole blood using a commercial DNA extraction kit (QiaGen, USA) following the standard manufacturer\'s protocol. The concentration of sample DNA was determined by a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE). The exon regions and flanking short intronic sequences of the SGCA gene were amplified using polymerase chain reaction (PCR), followed by direct sequencing of the PCR products (ABI, US) (NCBI Reference Sequence: NG_008889.1). Hitherto reported genetic abnormalities in LGMD-2D are listed in [Table 1](#tab1){ref-type="table"}.

3. Results {#sec3}
==========

The muscle biopsy showed dystrophic changes like contraction, regeneration ([Figure 1](#fig1){ref-type="fig"}), degeneration, necrosis, nuclear internalization, and fibrosis. In addition, many pathological immature myofibers were visualized using the neonatal myosin staining ([Figure 2](#fig2){ref-type="fig"}). Based on immunostaining, dystrophin and spectrin expressions were normal. Except for isolated deficient fibers, beta (*β*) sarcoglycan and delta (*δ*) sarcoglycan were present at normal levels, whereas *α*-SGC and *γ*-SGC were diffusely absent ([Figure 3](#fig3){ref-type="fig"}).

Based on analysis of the proband, we have identified a previously undetermined homozygous 7 bp deletion in exon 3 ([Figure 4](#fig4){ref-type="fig"}). A similar heterozygous deletion was found in both parents (Figures [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Location of this deletion was also indicated in [Table 1](#tab1){ref-type="table"}. In addition, there were no abnormalities in the dystrophin gene and the other sarcoglycan genes (SGCB, SGCD, and SGCG) in the patient and his parents.

4. Discussion {#sec4}
=============

Human SGCA cDNA from a human skeletal muscle library was isolated and sequenced in 1993. This gene consisted of 10 exons. The protein product of SGCA gene consisted of 387 amino acids with an extracellular N-terminus, a transmembrane domain, and an intracellular C-terminus. Northern blot analysis showed that human adhalin mRNA was expressed at the highest levels in skeletal muscle. It was also expressed in cardiac muscle and in the lung, but at much lower levels. On the contrary, adhalin mRNA was not detected in the brain. It was also reported that the adhalin mRNA from cardiac muscle was shorter relative to skeletal muscle and that the base sequence encoding the transmembrane domain was absent. It is known that LGMD-2D primarily affects skeletal muscles while brain and peripheral nerve functions are largely preserved. Briefly, the less severe cardiac dysfunction and lack of mental retardation in patients with LGMD-2D may be explained by the lower expression of *α*-SGC in cardiac muscle and the absence of adhalin expression in the brain \[[@B1], [@B3], [@B10]\]. In the patient described in this report, we did not find clinical evidence of cardiac involvement, decreased intellectual capacity, or denervation (as demonstrated by electromyography). The course of the disease in this case suggests that this novel deletion may cause a milder phenotype of LGMD-2D despite the diffuse absence of *α*-SGC and *γ*-SGC.

Immunohistochemical analysis of sarcolemmal proteins in muscle biopsies like dystrophin, SGCs, merosin, and dysferlin is an important part of the diagnostic evaluation of patients with muscular dystrophy. Reduced or absent sarcolemmal expression of one of the 4 SGCs can be found in patients with any type of LGMDs and also in patients with dystrophinopathies. It has previously been suggested that different patterns of SGC expression could predict the primary genetic defect and that genetic analysis could be directed by these patterns \[[@B5]--[@B8]\]. However, Klinge et al. \[[@B9]\] reported that residual SGC expression could be highly variable and an accurate prediction of the genotype could not be achieved. Babameto-Laku et al. \[[@B4]\] also determined that the concomitant absence of *α*-SGC and *γ*-SGC expression was caused by defects in the SGCA gene. Therefore, they recommended using antibodies against all four SGCs for immunoanalysis of skeletal muscle sections. Similarly, a concomitant reduction in dystrophin and any of the SGCs may illustrate the importance of considering coexisting dystrophinopathies in patients with sarcoglycan-deficient LGMD \[[@B9]--[@B13]\]. For this reason, it is not easy to decide whether the disease is a dystrophinopathy with defective expressions of SGCs or a LGMD with defective expression of dystrophin. However, in the patient described in this report, dystrophinopathies, such as DMD and BMD, were ruled out because the expression of sarcolemmal dystrophin was diffusely present and molecular tests for dystrophin gene were normal.

At present, more than 70 mutations have been reported in the SGCA gene that cause changes in the *α*-SGC glycoprotein. Approximately a two-thirds of mutations are missense mutations that generate a complete protein with a single residue substitution, whereas other mutations like nucleotide replacements, duplications, deletions, or insertions produce truncated, incomplete, or anomalous proteins. Almost all missense mutations map to the extracellular domain which is a critical region for the organization of SGCs and their association with dystroglycan. Only a single missense mutation maps to the intracellular domain and causes LGMD-2D in homozygous cases. Similarly, two mutations caused by deletions generate a normal extracellular portion of *α*-SGC and truncated intracellular tails. At present, there is no data about the intracellular tail of the *α*-SGC protein and its function \[[@B1], [@B10]--[@B14]\]. In the family described in this report, we discovered a novel deletion in the TACACCC site of exon 3 that would cause a frame-shift mutation. The past literature highlights that the prediction of pathological consequences associated with different mutations of SGCA gene is very complex. It is not clear whether this novel deletion generates a severe disease phenotype or whether it also has additional, undetermined consequences.

Patients with any of the LGMDs may be clinically indistinguishable from those with the primary dystrophinopathies. It is likely that the prevalence of LGMD is underestimated and a number of male patients are incorrectly diagnosed with DMD or BMD \[[@B13]\]. A definitive diagnosis rests on performing the appropriate immunohistochemical examination as well as doing a molecular analysis. A normal dystrophin staining pattern should be seen as well as an autosomal recessive mode of inheritance. In contrast, the patients with dystrophinopathies may show variable findings from a normal to a regional absence or a mosaic pattern of sarcolemmal staining with anti-SGCs antibodies which correspond to an abnormal organization of the cell-membrane-associated dystrophin glycoprotein complex. Therefore, it is necessary to perform a careful examination of the immunohistochemical staining as well as a genetic study in order to make the correct diagnosis.

In summary, this report describes a novel deletion that adds to the growing list of defects associated with LGMD-2D and further emphasizes the importance of systematic analysis of all related genes, instead of limiting the analysis to the one SGC gene that is hypothesized to be the cause of the abnormalities. In this study, we also highlight the complexity of staining patterns associated with sarcolemmal proteins and the importance of careful analysis of this staining pattern in order to narrow the differential diagnosis of muscular dystrophies.
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![Differences in the size and shape of myofibers as well as regeneration (HEx 200).](CRIG2014-248561.001){#fig1}

![Immature pathological fibers visualized with anti-neonatal myosin antibody staining (DABx 100).](CRIG2014-248561.002){#fig2}

![Diffuse absence of sarcolemmal *α*-SGC (a) and *γ*-SGC (d) expression and normal *β*-SGC (b) and *δ*-SGC (c) expression (DABx 200).](CRIG2014-248561.003){#fig3}
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![Paternal heterozygous del TACACCC site.](CRIG2014-248561.006){#fig6}

###### 

Nucleotide and amino acid sequences of *α*-SGC gene.

  ------- --------- --------- ----------- ----------- ----------- --------- --------- --------- ------ --------- --------- --------- --------- --------- ---------
  1\      ATG\      GCT\      GAG\        ACA\        CTC\        TTC\      TGG\      ACT\      CCT\   CTC\      CTC\      GTG\      GTT\      CTC\      CTG\
  1       Met       Ala       Glu         Thr         Leu         Phe       Trp       Thr       Pro    Leu       Leu       Val       Val       Leu       Leu

                                                                                                                                                         

  46\     GCA\      GGG\      CTG\        GGG\        GAC\        ACC\      GAG\      GCC\      CAG\   CAG\      ACC\      ACG\      CTA\      CAC\      CCA \
  16      Ala       Gly       Leu         Gly         Asp         Thr       Glu       Ala       Gln    Gln       Thr       Thr       Leu       His       Pro^\#^

                                                                                                                                                         

  91\     CTT \     GTG\      GGC\        CGT \       GTC\        TTT\      GTG\      CAC\      ACC\   TTG\      GAC\      CAT\      GAG\      ACG\      TTT\
  31      Leu^\#^   Val       Gly         Arg^\#^     Val         Phe       Val       His       Thr    Leu       Asp       His       Glu       Thr       Phe

                                                                                                                                                         

  136\    CTG\      AGC\      CTT\        CCT\        GAG\        CAT\      GTC\      GCT \     GTC\   CCA\      CCC\      GCT\      GTC\      CAC\      ATC\
  46      Leu       Ser       Leu         Pro         Glu         His       Val       Ala^\#^   Val    Pro       Pro       Ala       Val       His       Ile

                                                                                                                                                         

  181\    ACC\      TAC \     CAC\        GCC\        CAC\        CTC\      CAG\      GGA \     CAC\   CCA\      GAC\      CTG\      CCC\      CGG \     TGG\
  61      Thr       Tyr^\#^   His         Ala         His         Leu       Gln       Gly^\#^   His    Pro       Asp       Leu       Pro       Arg^\#^   Trp

                                                                                                                                                         

  226\    CTC\      CGC \     **TAC** \   **ACC** \   **C**AG \   CGC \     AGC\      CCC\      CAC\   CAC\      CCT\      GGC\      TTC\      CTC \     TAC \
  76      Leu       Arg^\#^   Tyr^\#\#^   Thr^\#\#^   Gln^\#\#^   Arg^\#^   Ser       Pro       His    His       Pro       Gly       Phe       Leu^\#^   Tyr^\#^

                                                                                                                                                         

  271\    GGC \     TCT\      GCC \       ACC\        CCA\        GAA\      GAT \     CGT \     GGG\   CTC\      CAG\      GTC\      ATT \     GAG\      GTC\
  91      Gly^\#^   Ser       Ala^\#^     Thr         Pro         Glu       Asp^\#^   Arg^\#^   Gly    Leu       Gln       Val       Ile^\#^   Glu       Val

                                                                                                                                                         

  316\    ACA\      GCC\      TAC\        AAT\        CGG \       GAC\      AGC\      TTT\      GAT\   ACC\      ACT\      CGG\      CAG\      AGG\      CTG\
  106     Thr       Ala       Tyr         Asn         Arg^\#^     Asp       Ser       Phe       Asp    Thr       Thr       Arg       Gln       Arg       Leu

                                                                                                                                                         

  361\    GTG\      CTG\      GAG\        ATT \       GGG\        GAC\      CCA\      GAA\      GGC\   CCC\      CTG\      CTG\      CCA\      TAC\      CAA\
  121     Val       Leu       Glu         Ile^\#^     Gly         Asp       Pro       Glu       Gly    Pro       Leu       Leu       Pro       Tyr       Gln

                                                                                                                                                         

  406\    GCC\      GAG \     TTC\        CTG \       GTG\        CGC \     AGC\      CAC\      GAT\   GCG\      GAG\      GAG\      GTG\      CTG\      CCC\
  136     Ala       Glu^\#^   Phe         Leu^\#^     Val         Arg^\#^   Ser       His       Asp    Ala       Glu       Glu       Val       Leu       Pro

                                                                                                                                                         

  451\    TCA\      ACA\      CCT\        GCC\        AGC\        CGC\      TTC\      CTC \     TCA\   GCC\      TTG\      GGG\      GGA\      CTC\      TGG\
  151     Ser       Thr       Pro         Ala         Ser         Arg       Phe       Leu^\#^   Ser    Ala       Leu       Gly       Gly       Leu       Trp

                                                                                                                                                         

  496\    GAG\      CCC\      GGA\        GAG\        CTT\        CAG\      CTG\      CTC \     AAC\   GTC \     ACC\      TCT\      GCC\      TTG\      GAC\
  166     Glu       Pro       Gly         Glu         Leu         Gln       Leu       Leu^\#^   Asn    Val^\#^   Thr       Ser       Ala       Leu       Asp

                                                                                                                                                         

  541\    CGT \     GGG\      GGC\        CGT\        GTC\        CCC\      CTT\      CCC\      ATT\   GAG\      GGC\      CGA\      AAA\      GAA\      GGG \
  181     Arg^\#^   Gly       Gly         Arg         Val         Pro       Leu       Pro       Ile    Glu       Gly       Arg       Lys       Glu       Gly^\#^

                                                                                                                                                         

  586\    GTA \     TAC\      ATT\        AAG\        GTG\        GGT\      TCT\      GCC\      TCA\   CCT \     TTT\      TCT\      ACT \     TGC\      CTG\
  196     Val^\#^   Tyr       Ile         Lys         Val         Gly       Ser       Ala       Ser    Pro^\#^   Phe       Ser       Thr^\#^   Cys       Leu

                                                                                                                                                         

  631\    AAG\      ATG\      GTG\        GCA\        TCC \       CCC\      GAT\      AGC\      CAC\   GCC\      CGC \     TGT\      GCC\      CAG \     GGC\
  211     Lys       Met       Val         Ala         Ser^\#^     Pro       Asp       Ser       His    Ala       Arg^\#^   Cys       Ala       Gln^\#^   Gly

                                                                                                                                                         

  676\    CAG\      CCT \     CCA \       CTT\        CTG\        TCT\      TGC \     TAC\      GAC\   ACC\      TTG\      GCA\      CCC \     CAC\      TTC\
  226     Gln       Pro^\#^   Pro^\#^     Leu         Leu         Ser       Cys^\#^   Tyr       Asp    Thr       Leu       Ala       Pro^\#^   His       Phe

                                                                                                                                                         

  721\    CGC\      GTT \     GAC\        TGG\        TGC\        AAT\      GTG \     ACC\      CTG\   GTG\      GAT\      AAG\      TCA\      GTG\      CCG\
  241     Arg       Val^\#^   Asp         Trp         Cys         Asn       Val^\#^   Thr       Leu    Val       Asp       Lys       Ser       Val       Pro

                                                                                                                                                         

  766\    GAG\      CCT\      GCA\        GAT\        GAG\        GTG\      CCC \     ACC\      CCA\   GGT\      GAT\      GGG\      ATC\      CTG\      GAG\
  256     Glu       Pro       Ala         Asp         Glu         Val       Pro^\#^   Thr       Pro    Gly       Asp       Gly       Ile       Leu       Glu

                                                                                                                                                         

  811\    CAT\      GAC \     CCG\        TTC\        TTC\        TGC\      CCA\      CCC\      ACT\   GAG\      GCC\      CCA\      GAC\      CGT \     GAC\
  271     His       Asp^\#^   Pro         Phe         Phe         Cys       Pro       Pro       Thr    Glu       Ala       Pro       Asp       Arg^\#^   Asp

                                                                                                                                                         

  856\    TTC\      TTG\      GTG\        GAT\        GCT\        CTG\      GTC\      ACC\      CTC\   CTG\      GTG\      CCC\      CTG\      CTG\      GTG\
  286     Phe       Leu       Val         Asp         Ala         Leu       Val       Thr       Leu    Leu       Val       Pro       Leu       Leu       Val

                                                                                                                                                         

  901\    GCC\      CTG\      CTT\        CTC\        ACC\        TTG\      CTG\      CTG\      GCC\   TAT\      GTC\      ATG \     TGC\      TGC\      CGG\
  301     Ala       Leu       Leu         Leu         Thr         Leu       Leu       Leu       Ala    Tyr       Val       Met^\#^   Cys       Cys       Arg

                                                                                                                                                         

  946\    CGG\      GAG\      GGA\        AGG\        CTG\        AAG\      AGA\      GAC\      CTG\   GCT\      ACC\      TCC\      GAC\      ATC\      CAG\
  316     Arg       Glu       Gly         Arg         Leu         Lys       Arg       Asp       Leu    Ala       Thr       Ser       Asp       Ile       Gln

                                                                                                                                                         

  991\    ATG\      GTC\      CAC\        CAC\        TGC\        ACC\      ATC\      CAC\      GGG\   AAC\      ACA\      GAG\      GAG\      CTG\      CGG\
  331     Met       Val       His         His         Cys         Thr       Ile       His       Gly    Asn       Thr       Glu       Glu       Leu       Arg

                                                                                                                                                         

  1036\   CAG\      ATG\      GCG\        GCC\        AGC\        CGC\      GAG\      GTG\      CCC\   CGG\      CCA\      CTC\      TCC\      ACC\      CTG\
  346     Gln       Met       Ala         Ala         Ser         Arg       Glu       Val       Pro    Arg       Pro       Leu       Ser       Thr       Leu

                                                                                                                                                         

  1081\   CCC\      ATG\      TTC\        AAT\        GTG\        CAC\      ACA\      GGT\      GAG\   CGG\      CTG\      CCT\      CCC\      CGC\      GTG\
  361     Pro       Met       Phe         Asn         Val         His       Thr       Gly       Glu    Arg       Leu       Pro       Pro       Arg       Val

                                                                                                                                                         

  1126\   GAC\      AGC\      GCC\        CAG\        GTG\        CCC\      CTC\      ATT\      CTG\   GAC\      CAG\      CAC\      TGA\                
  376     Asp       Ser       Ala         Gln         Val         Pro       Leu       Ile       Leu    Asp       Gln       His       Ter                 
  ------- --------- --------- ----------- ----------- ----------- --------- --------- --------- ------ --------- --------- --------- --------- --------- ---------

\*Note the previously determined missense mutations marked with \#. The present deletion was marked with \#\# and bold letters.
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